drugset / Trial / NCT00482391
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Phase 2
Completed
95 enrolled
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute · collabGlaxoSmithKline · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer.
Timeline
- Start
- 2007-03
- Primary completion
- 2011-07
- Completion
- 2011-07
Outcome
Missed primary endpoint
paper Dose-dense AC followed by PTL and then followed by TL was not feasible PMID 20479410 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 60 mg/m2 | — |
| Subject | Lapatinib | Small molecule | 1000 mg | Oral |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |